1.44
+0.02(+1.41%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.45 |
| Day High | 1.46 |
| Day Low | 1.44 |
| 52-Week High | 1.96 |
| 52-Week Low | 1.17 |
| Volume | 33,327 |
| Average Volume | 74,315 |
| Market Cap | 70.88M |
| PE | -6 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 1.39 |
| Change | 0.02 |
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
GlobeNewswire Inc.
Jan 29, 2026 11:00 PM GMT
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of t
2026 New Year’s Greetings from the CEO
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corpo
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf